SCHEMBL6175239

SCHEMBL6175239

O=C1NC(=S)SC1=Cc1ccc2c(c1)N(C(=O)O)CCCO2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.58
CLK1 P49759 1/20 0.58
CSNK2B P67870 1/20 0.58
CSNK2A1 P68400 1/20 0.58
DYRK1A Q13627 1/20 0.58
DYRK2 Q92630 1/20 0.58
DYRK1B Q9Y463 1/20 0.58
PIK3CG P48736 11/20 0.53
PTP4A3 O75365 1/20 0.51
MYC P01106 2/20 0.50
MAX P61244 1/20 0.50
IL1RN P18510 1/20 0.50
ERAP1 Q9NZ08 1/20 0.50
PIK3C2A O00443 2/20 0.48
PIK3C2B O00750 2/20 0.48
PIK3CA P42336 2/20 0.48
PRKDC P78527 2/20 0.48
PIK3R1 P27986 1/20 0.48
PIK3C3 Q8NEB9 1/20 0.48
PIK3CD O00329 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6176750 1.00 CSNK2A2 (0.58) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL6175199 0.94 CSNK2A2 (0.60) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL6173317 0.94 CSNK2A2 (0.60) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL6184334 0.89 PIK3CG (0.51) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL6184337 0.89 PIK3CG (0.51) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL6173708 0.88 CSNK2A2 (0.54) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL6173705 0.88 CSNK2A2 (0.54) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL6176542 0.87 CSNK2A2 (0.53) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL6176546 0.87 CSNK2A2 (0.53) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL6185079 0.87 PIK3CG (0.51) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581529-A1 BENZOXAZINES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3KS WARNER-LAMBERT COMPANY (US) 2005-10-05 EP disclosed
US-20040138199-A1 Benzoxazines and derivatives thereof as therapeutic agents GOGLIOTTI ROCCO DEAN (US) 2004-07-15 US disclosed
WO-2004056820-A1 BENZOXAZINES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3KS WARNER-LAMBERT COMPANY LLC (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138199-A1 Benzoxazines and derivatives thereof as therapeutic agents XDH, TBXA2R, TBXAS1 CSNK2A2 1130/4885CLK1 602/4885CSNK2B 1595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.